January 7, 2021
VIA FACSIMILE AND EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Washington, D.C. 20549
| Re: | Lexaria Bioscience Corp. |
| Registration Statement on Form S-1 (Registration No. 333-250326) | |
| Concurrence in Acceleration Request |
Ladies and Gentlemen:
H.C. Wainwright & Co., LLC (“Wainwright”), as managing underwriter for the above-referenced offering, hereby concurs in the request by Lexaria Bioscience Corp. that the effective date of the above-referenced registration statement be accelerated to 4:00 P.M. Eastern Time on Monday, January 11, 2021, or as soon as practicable thereafter, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act in connection with this offering.
| Very truly yours, |
| |
|
|
| |
| H.C. WAINWRIGHT & CO., LLC |
| |
|
|
|
|
| By: | /s/ Edward S. Silvera |
|
| Name: | Edward D. Silvera |
|
| Title: | Chief Operating Officer |
|
430 Park Avenue | New York, New York 10022 | 212.356.0500
Security services provided by H.C. Wainwright & Co., LLC | Member: FINRA/SIPC